Cerebrolysin vs Dihexa

Evidence-based comparison. Updated 2026.

Cerebrolysin carries stronger clinical evidence (Grade B) and is better suited for neuroprotection, stroke recovery, and traumatic brain injury, while Dihexa (Grade C) is oriented toward enhancing memory, learning, and synaptic plasticity in research contexts. Choose Cerebrolysin when the priority is neurological recovery or disease support, and Dihexa when the focus is cognitive enhancement and neuroplasticity amplification.

Side by side

	Cerebrolysin	Dihexa
Evidence	BEvidenceGrade BSmaller human trials or observational studies, or approved in 30+ countries	CEvidenceGrade CMainly animal or in-vitro studies, with limited human data
Regulatory	CompoundableCompoundableLegal to compound in the US, or approved in other jurisdictions or historically	Research onlyResearch onlyNo regulatory approval in any major jurisdiction. For research use only
Benefits	Neuroprotective and neurotrophic effects May improve cognitive function Supports stroke recovery Potential for Alzheimer's and dementia Enhances neuroplasticity	Enhances memory and learning capacity Supports neuroplasticity and synaptic growth Improves cognitive processing speed Promotes neuroprotection against damage Enhances NGF and BDNF signaling
Dosage	5-30 mL mL, Daily for 10-30 days	50-100 mcg, 1x daily
Route	Intravenous, Intramuscular	Subcutaneous
Category	Cognitive Enhancement	Cognitive Enhancement

Full research page

Cerebrolysin

Full research page

Dihexa

Which should you choose

Cerebrolysin delivers a broad mixture of neuropeptides that mimic endogenous neurotrophic factors to support neuronal survival and repair, while Dihexa is a targeted hexapeptide that amplifies NGF and BDNF signaling through AT4 receptor agonism to enhance synaptic growth and memory formation.

Choose Cerebrolysin when

Clinical evidence supports its use in stroke recovery and traumatic brain injury rehabilitation, with multiple human trials conducted.
Its compoundable regulatory status makes it more accessible through licensed compounding channels compared to research-only alternatives.
Its mechanism of reducing neuroinflammation and supporting cellular energy metabolism makes it appropriate for neurodegenerative conditions such as Alzheimer's disease and dementia.

Choose Dihexa when

Preclinical data suggests potent pro-cognitive effects, particularly for memory formation and learning capacity, in models where cognitive enhancement rather than injury recovery is the goal.
Its targeted action on AT4 receptors and neurotrophic signaling pathways makes it a specific tool for researchers studying long-term potentiation and synaptic plasticity.
Dihexa may be considered when the research interest centers on enhancing NGF and BDNF expression as a primary endpoint rather than as a secondary neuroprotective effect.

Stacking Cerebrolysin and Dihexa is not a well-documented protocol in published literature, though some researchers theorize complementary activity given their overlapping neurotrophic targets and differing primary mechanisms.

Questions people ask

Do Cerebrolysin and Dihexa work through the same pathways, and does that make them redundant when compared?

Both peptides engage NGF and BDNF signaling, but they do so through distinct mechanisms. Cerebrolysin acts as a broad neurotrophic mimetic that promotes neuronal survival and reduces neuroinflammation, while Dihexa specifically agonizes AT4 receptors to amplify synaptic plasticity and long-term potentiation. This mechanistic overlap is partial rather than complete, which means they are not fully redundant, though the degree of additive benefit in human models has not been established.

Which peptide has a faster onset of observable cognitive effects, Cerebrolysin or Dihexa?

Cerebrolysin studies in stroke and TBI populations typically report functional improvements over weeks to months of treatment, reflecting its role in neuronal repair and structural recovery. Dihexa preclinical data suggests relatively rapid modulation of synaptic signaling, though human timeline data is limited given its research-only status. In the absence of direct comparative human trials, no definitive onset comparison can be made between the two.

Is one peptide more appropriate than the other for age-related cognitive decline specifically?

Cerebrolysin has been studied in Alzheimer's disease and vascular dementia populations, providing clinical context for its use in age-related neurodegeneration with Grade B evidence. Dihexa has shown promise in animal models of cognitive aging through enhanced neurotrophic signaling, but lacks equivalent clinical trial data in human aging populations. For age-related decline with a clinical intervention framework, Cerebrolysin currently has a stronger evidentiary basis.

Can Cerebrolysin and Dihexa be stacked together, and are there known interaction concerns?

No published human studies have examined the combination of Cerebrolysin and Dihexa, and no formal interaction data exists. Their overlapping action on neurotrophic pathways raises theoretical questions about redundancy or excessive pathway stimulation, though neither agent is known to produce antagonistic effects on the other's primary targets. Researchers considering a stack should account for Dihexa's research-only status and the absence of safety data for combined use.

Not sure which fits your research goals?

Use the goal finder

Answer three questions and get a peptide recommendation ranked by evidence grade.

Find my peptide